GMP News - Regulatory Affairs

16.09.14

Revision of Classification of Advanced Therapy Medicinal Products

The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs. Read more.

more

07.08.14

EDQM updates Guideline on the "Requirements for revision/renewal of CEPs"

CEP holders have to consider new regulations when notifying changes to submitted application documents. Concerning this, the EDQM updated the corresponding guideline. Read more here.

more

07.08.14

FDA defines Goal Dates for the Processing of Changes in Generics Authorisation Applications

The FDA is committed to compliance with certain deadlines for the processing of change applications and amendments in the approval process for generic drugs. Two recently published "Guidances for Industry" provide some information. Read more.

more

08.07.14

How can a CEP for a starting material be used in a CEP application for an API?

A CEP for a starting material offers several advantages, because it can be used for applying for an API CEP, which reduces the effort in the application process. However, this is linked to various conditions, which are described in a new document of the EDQM. Read more about this.

more

08.07.14

When can a CEP be withdrawn?

In which cases does the EDQM temporary suspend an existing CEP or definitively withdraw it? When can an ongoing CEP application procedure be closed? You can find answers to those questions in a new document of the EDQM. Read more here.

more

08.07.14

Stability Data for ANDAs in the USA: a new Q&A Document of the FDA provides further Clarity

The applicant for an ANDA in the USA has to submit data of several stability tests. The FDA guidance on this topic coming into force last year left open some issues, however, that now are clarified with a questions and answers document published lately. Read more.

more

23.04.14

New EMA Guideline on Stability Testing for Applications for Variations

The submission of a variations application for a marketing authorisation often includes the submission of stability data. This is particularly applicable to cases in which critical quality characteristics of the medicinal products are concerned. A new EMA Guideline sets rules to the requirements on different variations scenarios. Read more here.

more

23.04.14

EMA: Changes to Handling of Variations

The European Medicines Agency (EMA) is establishing new roles for handling variations. Read more.

more

10.04.14

New FDA Guideline on Size, Shape and Physical Attributes of Generics

Companies who want an authorisation for generic tablets or capsules in the USA should consider certain requirements with regard to the physical attributes of these dosage forms. The provisions can be found in a FDA Guidance for Industry recently published. Read more here.

more

10.04.14

Post-Approval Changes: new FDA Guidance

The US FDA has published a new guidance on post-approval changes with a new list of changes that might be appropriate to report in an annual report. Read more.

more

19.03.14

Industry Proposals for Addressing Post-Approval Change Burdens Include Harmonizing on Commitments and Classifications

Biopharmaceutical firms are calling for a global effort to decrease their heavy post-approval change filing burdens that would clarify and harmonize change classification and submission requirements on a risk-based foundation. Read on.

more

28.01.14

"Reception denied!" - the new FDA "Refuse-to-Receive" Guidance for Generics Applications

Errors when compiling an application for authorisation for a generic drug in the United States can be really expensive. It is not only important to ensure the completeness of the documents, but also to pay attention to deadlines with regard to various fees. Learn more here.

more

28.01.14

Update: Electronic Submission of Marketing Authorisation Dossiers

Since the 1st of January 2010, only electronical submissions for marketing authorisations within the centralised procedure can be accepted. A few significant details about the procedure and the standards have been  recently changed. Read more here about the current requirements for the electronical submission of  dossiers.

more

16.10.13

Black Triangle: a New EU Requirement

The use of a black triangle-shaped warning symbol will be required as of January 2014 for drugs containing new APIs and biological products (including biosimilars) to enhance medicinal products safety. More information can be found in the News.

more

01.10.13

FDA publishes revised Guidance for Applicants of Marketing Authorisations for Generics

What do applicants for marketing authorisations of generic products absolutely have to observe is laid down in a FDA Guidance on fees and procedural issues within the framework of the Generic Drug User Fee Act (GDUFA). Read more on the topic.

more

GMP Newsletter

Sign up for the free of charge newsletters.

Sign up now!

GMP Conferences by Topics